News articles about iRadimed Corporation (NASDAQ:IRMD) have trended somewhat positive on Friday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. iRadimed Corporation earned a news impact score of 0.13 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 45.465193766889 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several brokerages have recently issued reports on IRMD. ValuEngine upgraded iRadimed Corporation from a “sell” rating to a “hold” rating in a report on Friday, October 6th. Zacks Investment Research lowered iRadimed Corporation from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Roth Capital upgraded iRadimed Corporation from a “neutral” rating to a “buy” rating and lifted their price target for the company from $9.00 to $12.00 in a report on Monday, July 31st. Finally, TheStreet upgraded iRadimed Corporation from a “d” rating to a “c-” rating in a report on Friday, June 23rd.
iRadimed Corporation (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, July 28th. The medical equipment provider reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.07. iRadimed Corporation had a return on equity of 8.98% and a net margin of 11.61%. The firm had revenue of $5.50 million during the quarter, compared to analysts’ expectations of $5.41 million. During the same period in the prior year, the firm posted $0.24 earnings per share. The business’s quarterly revenue was down 44.4% compared to the same quarter last year.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
What are top analysts saying about iRadimed Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for iRadimed Corporation and related companies.